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• Adenoviruses (AdV) are double-stranded 
DNA viruses that are rare, but well 
recognized causes of morbidity and allograft 
dysfunction.  
• We have previously shown that adenovirus 
nephritis (AdVN) can present with 
granulomatous or neutrophilic 
tubulointerstitial nephritis in kidney biopsies 
(See Figure). 
• In kidney transplant recipients, certain 
clinical and histologic features should raise 
concern for adenovirus nephritis (AdN).  
• There are many options to management, 
ranging from supportive therapy to the use 
of AdV-directed therapy.  
• Here we report eight cases of AdVN in kidney 
transplant recipients and their clinical 
course, management and outcomes.  
• A retrospective search to identify cases of 
AdVN in renal transplant recipients from 
2009-2016 at the Emory Transplant Center 
was performed.  
• The diagnosis of AdVN was confirmed by 
immunostaining on kidney transplant biopsy 
in 7/8 cases.   
• The diagnosis was made clinically in case 8 
due to inadequate sampling of the biopsy. 
• The following information was collected and 
recorded on all patients (see Table): 
• Demographic data (age and gender) 
• Number of days between transplantation 
and biopsy showing AdVN 
• Serum creatinine level at time of biopsy 
• Baseline creatinine level 
• Serum/urine AdV level at time of biopsy  
• Evidence of concurrent rejection 
• Evidence of concurrent infection 
• Treatment regimen 
• Median time from transplant to development of 
adenovirus infection:  50 days. 
  
• All patients presented with constitutional 
symptoms: dysuria, hematuria, and proteinuria.  
• 5/8 patients presented with fever, 5/8 with 
diarrhea and 2/8 with diarrhea and respiratory 
symptoms. 
 
• The peak serum creatinine increased by a median 
of 83% from baseline. 
 
• Of the 2 that did not receive AdV-directed therapy, 
1 had resolution of the viremia after 42 days. There 
was no documentation of viremia clearance for the 
second, although they had a benign clinical 
course. 
 
• The 4 who received ribavirin cleared the virus at a 
median of 78 days. 
 
• The 1 who received brincidofovir cleared the virus 
at 22 days. 
 
• Proteinuria and hematuria improved or resolved in 
all patients irrespective of treatment regimen. 
 
• All patients were noted to have a concurrent viral 
or bacterial complication (See Table) at the time of 
management for AdVN. 
• This case series summarizes the range of clinical 
features and management of AdVN. 
• Treatment regimen varied, but clinical resolution 
was noted in all cases and was most profound 
with brincidofovir.  
• Despite the morbidity of AdVN, if managed and 
monitored closely, resolution can be achieved with 
good outcomes in renal function in kidney 
transplant recipients. 
• Additional study of cases of AdVN without AdV-
directed therapy are required before supportive 
therapy can be considered a universally viable 
option. 
• Overall, our study demonstrates the need to 
account for the management of simultaneous 
rejections, other viremias, and potential side 
effects of the therapeutics.  
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TABLE:  All eight patients had a concurrent infection with AdVN.  2 of 4 patients had a prior biopsy showing cell mediated rejection.  All eight patients had 
macroscopic hematuria.  CR=creatinine, TX=transplant, AMR=antibody mediated rejection, IS=immunosuppression, SNR=site not recorded. 
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CASE PATIENT GENDER AGE 
DAYS 
 FROM TX 
REJECTION 
 (CURRENT/PRIOR) 
 BIOPSY 
SERUM 
CR 
BASE- 
LINE CR HEMATURIA 
SERUM (URINE) 
ADENOVIRUS 
LEVEL 
IS REGIMEN 
PRIOR TO BX HISTOLOGIC PATTERN TREATMENT 
OTHER 
INFECTION 
1 1 Male  74 397 AMR/NONE 2.0 1.5 MACROSCOPIC 
"Detected" in 
urine only 
PROGRAF, 
PREDNISONE, 
CELLCEPT 
GRANULOMAS, TUBULAR NECROSIS                                        RIBAVIRIN BK VIREMIA 
2 2 Male  59 50 NONE/BANFF IIA  3.1 2.0 MACROSCOPIC 
"Positive" 
(>2,000,000 copies/mL) 
PROGRAF,  
PREDNISONE, 
CELLCEPT                                                 
OBLITERATIVE TUBULITIS WITH NECROSIS, 
MIXED MONONUCLEAR AND NEUTROPHILIC 
INTERSTITIAL INLFLAMMATION, VAGUE 
GRANULOMA FORMATION, "SMUDGE 
CELLS" 
RIBAVIRIN 
EBV AND 
PARVOVIRUS 
VIREMIA 
3 3 Male  63 13 NONE/NO PRIOR BIOPSY 5.0 3.8 MACROSCOPIC 
2,856 copies/mL 
(399,376 copies/mL)  
PROGRAF,  
PREDNISONE, 
CELLCEPT 
PATCHY (MIXED) TUBULOINTERSTITIAL 
INFLAMMATION (MONONUCLEAR AND 
NEUTROPHILIC) 
NONE 
(SUBSEQUENT  
BIOPSY) 
EBV VIREMIA 
4 3 Male  63 33 NONE /NONE 4.8 3.8 MACROSCOPIC 
2,856 copies/mL 
(399,376 copies/mL)  
PROGRAF, 
PREDNISONE, 
CELLCEPT 
POORLY FORMED GRANUOMAS, 
OBLITERATIVE TUBULITIS WITH 
COAGULATIVE NECROSIS 
RIBAVIRIN EBV VIREMIA 
5 4 Female  42 1,414 NONE/BANFF IB 2.4 1.0 MACROSCOPIC "POSITIVE" (N/A) 
PREDNISONE, 
CELLCEPT, 
BELATACEPT 
NECROTIZING GRANULOMATOUS 
TUBULOINTERSTITIAL INFLAMMATION WITH 
A MIXED CELLUAR INFILTRATE 
SUPPORTIVE 
CARE 
S. AUREUS IN SERUM 
AND URINE, 
EBV VIREMIA  
6 5 Male  24 52 
DSA PRESENT/NO PRIOR 
BIOPSY 
2.4 1.3 MACROSCOPIC 
"POSITIVE" 
(>2,000,000) 
PREDNISONE, 
PROGRAF, 
BELATACEPT 
NEUTROPHILIC TUBULITIS WITH 
FIBRINOPURULENT/NECROTIC DEBRIS 
SUPPORTIVE  
CARE 
CMV VIREMIA  
7 6 Female  56 43 NONE/NO PRIOR BIOPSY 2.0 1.5 MACROSCOPIC 
SNR: 158,269 
copies/mL 
PREDNISONE, 
PROGRAF, 
CELLCEPT 
COAGULATIVE NECROSIS OF TUBULES WITH 
MONONUCLEAR TUBULITIS AND "SMUDGE 
CELLS" 
RIBAVIRIN 
AND IVIG 
E. COLI UTI 
8 7 Male 24 20 NONE/NO PRIOR BIOPSY 1.5 1.5 MACROSCOPIC “POSITIVE” (N/A) 
BELATACEPT, 
CELLCEPT, 
TACROLIMUS, 
PREDNISONE 
“NEGATIVE” STAINING 
 (INADEQUATE SAMPLE) 
BRINCIDOFIVIR  
REDUCED IS 
BK VIREMIA 
B C A 
F 
FIGURE: A,B: Hematoxylin and Eosin (H&E) and corresponding AdV immunohistochemistry (IHC) showing necrotizing, 
granulomatous AdVN.  C:  Electron microscopy showing an AdV particle.  D,E:  H&E showing severe neutrophilic tubulitis 
with reactive IHC for AdV.  F: “Smudge cells” in a granulomatous focus of AdVN.  
D E 
43% 
29% 
14% 
14% 
Pie Chart Showing Breakdown of 
Therapeutic Regimen 
Ribavirin Supportive Care
Ribavirin and IVIG Brincidofivir
